Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.

ISBD task force attention-deficit hyperactivity disorder, cognitive impairment bipolar disorder medication recommendations systematic review

Journal

Bipolar disorders

ISSN: 1399-5618

Titre abrégé: Bipolar Disord

Pays: Denmark

ID NLM: 100883596

Informations de publication

Date de publication:
03 Mar 2024

Historique:

medline: 4 3 2024

pubmed: 4 3 2024

entrez: 4 3 2024

Statut: aheadofprint

Résumé

Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD. We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials. Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias. Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials.

RESULTS RESULTS

Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias.

CONCLUSIONS CONCLUSIONS

Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.

Identifiants

DOI: 10.1111/bdi.13414 PMID: 38433530

pubmed: 38433530

doi: 10.1111/bdi.13414

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005;57(11):1467-1473. doi:10.1016/j.biopsych.2005.01.036

Schiweck C, Arteaga-Henriquez G, Aichholzer M, et al. Comorbidity of ADHD and adult bipolar disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;124:100-123. doi:10.1016/j.neubiorev.2021.01.017

Torres I, Gomez N, Colom F, et al. Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. Acta Psychiatr Scand. 2015;132(5):389-399. doi:10.1111/acps.12426

Salarvan S, Sparding T, Clements C, Ryden E, Landen M. Neuropsychological profiles of adult bipolar disorder patients with and without comorbid attention-deficit hyperactivity disorder. Int J Bipolar Disord. 2019;7(1):14. doi:10.1186/s40345-019-0149-9

Pievsky MA, McGrath RE. The neurocognitive profile of attention-deficit/hyperactivity disorder: a review of meta-analyses. Arch Clin Neuropsychol. 2018;33(2):143-157. doi:10.1093/arclin/acx055

Ott C, Mine H, Petersen JZ, Miskowiak K. Relation between functional and cognitive impairments in remitted patients with bipolar disorder and suggestions for trials targeting cognition: an exploratory study. J Affect Disord. 2019;257:382-389. doi:10.1016/j.jad.2019.07.030

Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16(3):217-229. doi:10.1111/bdi.12148

Burdick KE, Millett CE. Cognitive heterogeneity is a key predictor of differential functional outcome in patients with bipolar disorder. Eur Neuropsychopharmacol. 2021;53:4-6. doi:10.1016/j.euroneuro.2021.06.008

Kjaerstad HL, Sohol K, Vinberg M, Kessing LV, Miskowiak KW. The trajectory of emotional and non-emotional cognitive function in newly diagnosed patients with bipolar disorder and their unaffected relatives: a 16-month follow-up study. Eur Neuropsychopharmacol. 2023;67:4-21. doi:10.1016/j.euroneuro.2022.11.004

Sankar A, Ziersen SC, Ozenne B, et al. Association of neurocognitive function with psychiatric hospitalization and socio-demographic conditions in individuals with bipolar and major depressive disorders. EClinicalMedicine. 2023;58:101927. doi:10.1016/j.eclinm.2023.101927

Torres I, Sole B, Corrales M, et al. Are patients with bipolar disorder and comorbid attention-deficit hyperactivity disorder more neurocognitively impaired? Bipolar Disord. 2017;19(8):637-650. doi:10.1111/bdi.12540

Kleinman A, Caetano SC, Brentani H, et al. Attention-based classification pattern, a research domain criteria framework, in youths with bipolar disorder and attention-deficit/hyperactivity disorder. Aust N Z J Psychiatry. 2015;49(3):255-265. doi:10.1177/0004867414557957

Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149-162. doi:10.1111/acps.12133

Burdick KE, Russo M, Frangou S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083-3096. doi:10.1017/S0033291714000439

Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: associations with functional abilities. J Affect Disord. 2016;205:378-386. doi:10.1016/j.jad.2016.08.018

Torres I, Garriga M, Sole B, et al. Functional impairment in adult bipolar disorder with ADHD. J Affect Disord. 2018;227:117-125. doi:10.1016/j.jad.2017.09.037

Grunhage F, Schulze TG, Muller DJ, et al. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry. 2000;5(3):275-282. doi:10.1038/sj.mp.4000711

Hahn MK, Blakely RD. The functional impact of SLC6 transporter genetic variation. Annu Rev Pharmacol Toxicol. 2007;47:401-441. doi:10.1146/annurev.pharmtox.47.120505.105242

Hansen FH, Skjorringe T, Yasmeen S, et al. Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest. 2014;124(7):3107-3120. doi:10.1172/JCI73778

Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology. 2005;49(6):724-736. doi:10.1016/j.neuropharm.2005.08.003

Schmitt KC, Rothman RB, Reith ME. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J Pharmacol Exp Ther. 2013;346(1):2-10. doi:10.1124/jpet.111.191056

Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60(2):141-151. doi:10.1016/j.biopsych.2005.10.024

Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98(12):6917-6922. doi:10.1073/pnas.111134598

Boonstra AM, Kooij JJ, Buitelaar JK, et al. An exploratory study of the relationship between four candidate genes and neurocognitive performance in adult ADHD. Am J Med Genet B Neuropsychiatr Genet. 2008;147(3):397-402. doi:10.1002/ajmg.b.30595

Morris KA, Grace SA, Woods W, Dean B, Rossell SL. The influence of COMT rs4680 on functional connectivity in healthy adults: a systematic review. Eur J Neurosci. 2020;52(8):3851-3878. doi:10.1111/ejn.14748

Miskowiak KW, Kjaerstad HL, Stottrup MM, et al. The catechol-O-methyltransferase (COMT) Val158Met genotype modulates working memory-related dorsolateral prefrontal response and performance in bipolar disorder. Bipolar Disord. 2017;19(3):214-224. doi:10.1111/bdi.12497

Miskowiak KW, Petersen CS. Neuronal underpinnings of cognitive impairment and - improvement in mood disorders. CNS Spectr. 2019;24(1):30-53. doi:10.1017/S1092852918001062

Zarp Petersen J, Varo C, Skovsen CF, et al. Neuronal underpinnings of cognitive impairment in bipolar disorder: a large data-driven functional magnetic resonance imaging study. Bipolar Disord. 2022;24(1):69-81. doi:10.1111/bdi.13100

Cubillo A, Halari R, Smith A, Taylor E, Rubia K. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex. 2012;48(2):194-215. doi:10.1016/j.cortex.2011.04.007

Rubia K. Cognitive neuroscience of Attention Deficit Hyperactivity Disorder (ADHD) and its clinical translation. Front Hum Neurosci. 2018;12:100. doi:10.3389/fnhum.2018.00100

Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121. doi:10.1523/JNEUROSCI.21-02-j0001.2001

Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155(10):1325-1331. doi:10.1176/ajp.155.10.1325

Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711. doi:10.1016/S0893-133X(02)00346-9

Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13(6):770-776. doi:10.1101/lm.298006

Kowalczyk OS, Cubillo AI, Smith A, et al. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019;29(10):1102-1116. doi:10.1016/j.euroneuro.2019.07.139

Chamberlain SR, Hampshire A, Muller U, et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry. 2009;65(7):550-555. doi:10.1016/j.biopsych.2008.10.014

Clerkin SM, Schulz KP, Halperin JM, et al. Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biol Psychiatry. 2009;66(4):307-312. doi:10.1016/j.biopsych.2009.04.013

Berk M, Dodd S, Kauer-Sant'anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl. 2007;434:41-49. doi:10.1111/j.1600-0447.2007.01058.x

Pathak G, Ibrahim BA, McCarthy SA, Baker K, Kelly MP. Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures. Neuropharmacology. 2015;95:434-447. doi:10.1016/j.neuropharm.2015.04.026

Hegerl U, Sander C, Olbrich S, Schoenknecht P. Are psychostimulants a treatment option in mania? Pharmacopsychiatry. 2009;42(5):169-174. doi:10.1055/s-0029-1220888

Hegerl U, Mergl R, Sander C, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). Eur Neuropsychopharmacol. 2018;28(1):185-194. doi:10.1016/j.euroneuro.2017.11.003

Viktorin A, Ryden E, Thase ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry. 2017;174(4):341-348. doi:10.1176/appi.ajp.2016.16040467

Calabrese JR, Frye MA, Yang R, Ketter TA, Armodafinil Treatment Trial Study Network. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Psychiatry. 2014;75(10):1054-1061. doi:10.4088/JCP.13m08951

Ketter TA, Amchin J, Frye MA, Gross N. Long-term safety and efficacy of armodafinil in bipolar depression: a 6-month open-label extension study. J Affect Disord. 2016;197:51-57. doi:10.1016/j.jad.2016.02.050

McIntyre RS, Alsuwaidan M, Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013;28(5):421-427. doi:10.1002/hup.2325

Miskowiak KW, Seeberg I, Jensen MB, et al. Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: a systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2022;24(4):354-374. doi:10.1111/bdi.13193

Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613-623. doi:10.2165/11315280-000000000-00000

Kumar R. Approved and investigational uses of modafinil. Drugs. 2008;68:1803-1839. doi:10.2165/00003495-200868130-00003

Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311-320. doi:10.1089/cap.2000.10.311

Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10(10):CD009504. doi:10.1002/14651858.CD009504.pub2

Van Meter AR, Perez-Rodriguez MM, Braga RJ, et al. Pramipexole to improve cognition in bipolar disorder: a randomized controlled trial. J Clin Psychopharmacol. 2021;41(4):421-427. doi:10.1097/JCP.0000000000001407

Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org

Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898

Ahmadpanah M, Pezeshki R, Soltanian AR, et al. Influence of adjuvant clonidine on mania, sleep disturbances and cognitive performance - results from a double-blind and placebo-controlled randomized study in individuals with bipolar I disorder during their manic phase. J Psychiatr Res. 2022;146:163-171. doi:10.1016/j.jpsychires.2021.12.035

Lipschits JM, Perez-Rodriguez M, Majd M, et al. Modafinil's effects on cognition and sleep quality in affectively stable patients with bipolar disorder: a pilot study. Front Psych. 2023;14:1246149.

Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1445-1453. doi:10.1097/chi.0b013e31814b8d3b

Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003;53(11):978-984. doi:10.1016/s0006-3223(03)00067-2

Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162(1):58-64. doi:10.1176/appi.ajp.162.1.58

Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde LA. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553-561. doi:10.1089/cap.2009.0037

Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363-1370. doi:10.4088/JCP.09m05900gry

Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242-1249. doi:10.1176/appi.ajp.2007.06060981

Frye MA, Amchin J, Bauer M, Adler C, Yang R, Ketter TA. Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord. 2015;3(1):34. doi:10.1186/s40345-015-0034-0

Grossman F, Potter WZ, Brown EA, Maislin G. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord. 1999;56(2-3):237-243. doi:10.1016/s0165-0327(99)00041-5

Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015;181:87-91. doi:10.1016/j.jad.2015.04.012

McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(1):6-13. doi:10.1097/YIC.0000000000000051

McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4(3):207-213. doi:10.1034/j.1399-5618.2002.01189.x

Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131. doi:10.1192/bjp.bp.105.013045

Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55(9):391-393.

Bradley AJ, Webb-Mitchell R, Hazu A, et al. Sleep and circadian rhythm disturbance in bipolar disorder. Psychol Med. 2017;47(9):1678-1689. doi:10.1017/S0033291717000186

Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry. 2011;11:70. doi:10.1186/1471-244X-11-70

Miskowiak KW, Burdick KE, Martinez-Aran A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2017;19(8):614-626. doi:10.1111/bdi.12534

Miskowiak KW, Burdick KE, Martinez-Aran A, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord. 2018;20(3):184-194. doi:10.1111/bdi.12595